Dr. Michael Ackermann, PhD, MBA

Dr. Michael Ackermann, PhD, MBA has an extensive work experience in the field of technology and healthcare. Dr. Michael began their career in 1990 as a District Manager for US Sales at Eli Lilly and Company. Dr. Michael then held various roles at the same company, including Group Sales Leader, ADHD Business Unit Leader, Group Brand Leader, Director of Sales Administration Primary Care, Director of Business Intelligence & Analytics, and Manager of US Strategic Pricing. In 2012, they Co-Founded and became President of AB Collaborative Investment, an Angel Investment company focusing on start-up and local/regional growth companies. In 2013, they became a Board Member and Acting President of Magnatas, a boutique consulting firm. In 2015, they Co-Founded and became the Chief Business Officer and Board Member of Arrivo BioVentures LLC. In 2019, they became a Board Member of transOMIC technologies inc. In 2021, they became the Managing Director of Solas BioVentures. In 2022, they became a Board Member of Revibe Technologies.

Dr. Michael Ackermann, PhD, MBA began their educational journey at Hampden-Sydney College, where they earned a BS in Biology in 1980. Dr. Michael then continued on to Virginia Commonwealth University School of Medicine, where they began their PhD program in Microbiology in 1980. In 1982, they transferred to Drexel University College of Medicine and completed their PhD in Immunology in 1985. Dr. Michael then went on to UNC Kenan-Flagler Business School to earn their MBA in General Management in 1990. Following this, they completed a Fogerty International Fellowship at the National Institute of Health for Postdoctoral Studies in Immunology. Dr. Michael has also completed Executive Education at Harvard Business School in Organizational Leadership.